文献速递妇科

宫颈癌术后大分割调强放疗:前瞻性2期试验(POHIM_RT研究)

Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
PubMed 文献 · Gynecol Oncol · 2025-05-30

这项2期非随机多中心试验纳入61例根治性子宫切除术后适合辅助放疗的宫颈癌患者,全盆腔IMRT 40 Gy/16次。主要终点为≥3级急性胃肠、泌尿和血液学毒性,发生率为1.6%(90%CI 0-3.7%)。中位随访39.5个月,3年无病生存率87.1%,未报告≥3级晚期毒性。

要点

  • 根治性子宫切除术后宫颈癌患者接受全盆腔大分割IMRT 40 Gy/16次。
  • ≥3级急性胃肠、泌尿和血液学毒性发生率为1.6%(90%CI 0-3.7%)。
  • 中位随访39.5个月,3年无病生存率87.1%,未报告≥3级晚期毒性。

核心结论

  • 根治性子宫切除术后大分割IMRT严重毒性发生率低且疾病控制有效,提示可作为常规分割的可行替代方案。
  • 作者指出需要进一步随机对照试验来验证本研究结果。

研究设计与样本

  • 2期非随机多中心试验,纳入61例根治性子宫切除术后适合辅助放疗的宫颈癌患者。
  • 参与者接受全盆腔IMRT 40 Gy分16次照射。
  • 主要终点为≥3级急性胃肠、泌尿和血液学毒性发生率。
  • 次要终点包括患者报告的生活质量和无病生存期(DFS)。
  • 急性毒性采用美国国家癌症研究所常见不良事件评价标准v4.0监测。

主要发现

  • ≥3级急性毒性发生率为1.6%(90%置信区间0-3.7%)。
  • 中位随访39.5个月,3年DFS率为87.1%。
  • 随访期间未报告≥3级晚期毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需要进一步随机对照试验来验证本研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study evaluates the safety and efficacy of hypofractionated intensity-modulated radiation therapy (IMRT) following radical hysterectomy. METHODS: This phase II, non-randomized multicenter trial included 61 patients with cervical cancer who were eligible for adjuvant RT after radical hysterectomy. Participants received 40 Gy in 16 fractions using IMRT to whole pelvis. The primary endpoint was the incidence of grade 3 or higher acute gastrointestinal, genitourinary, and hematologic toxicities. Secondary endpoints included patient-reported quality of life and disease-free survival (DFS). Acute toxicities were monitored using the National Cancer Institute's Common Terminology Criteria for Adverse Events v4.0. RESULTS: Among the participants, the incidence of grade 3 or higher acute toxicities was 1.6 % (90 % confidence interval, 0-3.7 %). After a median follow-up of 39.5 months, the 3-year DFS rate was 87.1 %, and no grade ≥ 3 late toxicities were reported during the follow-up period. CONCLUSION: Hypofractionated IMRT post-radical hysterectomy demonstrated low severe toxicity rates and effective disease control, suggesting a feasible alternative to conventional fractionation. However, further randomized comparative trials are required to validate the results of this study. TRIAL REGISTRATION: Registered on ClinicalTrials.gov, NCT03239626.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Cho WK, Park W, Kim SW, et al. Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study). Gynecol Oncol. 2025. PMID: 40449127. doi:10.1016/j.ygyno.2025.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。